Please login or register first to view this content.
Hematological Disorders Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
NEWS & FEATURES
First Gene Therapy for Hemophilia B Gets FDA Approval
Patiromer Use for Acute Hyperkalemia Characterized
RAAS Inhibitor Discontinuation After Hyperkalemia Tied to Adverse Outcomes
Intravenous vs Oral Iron Does Not Increase CKD Risk
Tecvayli Approved for Relapsed or Refractory Multiple Myeloma
Rolvedon Now Available for Chemotherapy-Induced Neutropenia
FDA Accepts Resubmitted BLA for Valoctocogene Roxaparvovec for Hemophilia A
September 2022 Recap: Drug Pipeline Updates
Lanadelumab Gets Priority Review for Pediatric Hereditary Angioedema
AAP Issues Guidance for Assessing Bleeding Disorders When Child Abuse Suspected
Valoctocogene Roxaparvovec BLA Resubmitted for Hemophilia A
Rolvedon Approved for Chemotherapy-Induced Neutropenia
August 2022: Notable Drug Approvals
Stimufend, a Biosimilar to Neulasta, Gets FDA Approval
Investigational CRISPR Therapy Gets Orphan Drug Status for Hereditary Angioedema
Once-Weekly Efanesoctocog Alfa Gets Priority Review for Hemophilia A
Zynteglo Approved as First Gene Therapy for Beta-Thalassemia
Guideline Updated for Managing Hyperbilirubinemia in Newborns